Comment from Advancing American Freedom Foundation

Summary: The Advancing American Freedom Foundation opposes GenBioPro's petition, arguing that the FDA should not refrain from restricting access to mifepristone but should instead reinstate stricter Risk Evaluation and Mitigation Strategies (REMS). They contend that mifepristone poses significant health risks to women and that the FDA's current policies prioritize abortion access over patient safety.